CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 61 enrolled
Drug / intervention
Zoledronic Aciddrug
Likely dose
Zoledronic Acid 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03087851
NCT03087851Phase 4Completed
CompareCT.gov

Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis

Aarhus University Hospital·interventional·Posted Mar 23, 2017·Updated Feb 21, 2021

In Brief

A Phase 4 clinical trial evaluating Zoledronic Acid for Osteoporosis. Completed, enrolled 61 participants across 1 site.

Detailed Summary

Denosumab is an antibody against receptor-activator of nuclear factor kappa-B ligand that prevents recruitment and differentiation of mature osteoclasts. Treatment markedly decrease bone resorption and fracture risk, and many patients will reach osteopenic bone mineral density (BMD) levels on treatment with denosumab. The treatment effect on bone turnover and BMD has, however, been demonstrated to be reversible. This study will show if the bone mass can be maintained by administrating zoledronic acid and if timing of the first dose of zoledronic acid after last dose of denosumab matters.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesDenmark
CollaboratorsUniversity of Aarhus, Amgen

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 23, 2017
Enrollment StartMar 13, 2017
Primary CompletionAug 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 9.3 years ago

Interventions

Zoledronic Aciddrug

Intravenous infusion of 5 mg zoledronic acid